Featured Article Academic Journal Main Category: Stroke Also Included In: Nutrition / Diet;Diabetes Article Date: 15 Aug 2013 - 8:00 PDT

Current ratings for: Mediterranean diet 'reduces genetic stroke risk'

3.5 (2 votes)

4.5 (2 votes)

Scientists say they have discovered that the Mediterranean diet may prevent a genetic risk of stroke since it appears to interact with a particular gene variant usually associated with type 2 diabetes.

Researchers from the Jean Mayer USDA Human Nutrition Research center on Aging (USDA HNRCA) at Tufts University, and the CIBER Fisiopatologa de la Obesidad y Nutricion in Spain, conducted the study, which was published in the journal Diabetes Care.

The research team analyzed 7,018 men and women involved in the Prevencion con Dieta Mediterranea (PREDIMED) trial. The trial, carried out over a 5-year period, looked at whether a Mediterranean or a low-fat controlled diet had an effect on the risk of cardiovascular disease, stroke and heart attack, and whether genetics played a part in this.

Prior to the trial, participants were also required to complete food frequency questionnaires, in order to see how closely participants followed a Mediterranean diet.

The study focused on a particular variant found in the Transcription Factor 7-like 2 (TCF7L2) gene. The variant is commonly involved in glucose metabolism and can lead to the development of type 2 diabetes. The researchers say this gene variant's link to heart disease has previously been unclear.

Around 14% of the PREDIMED participants were found to be homozygous carriers, meaning they possessed two copies of this gene variant.

View post:
Mediterranean diet 'reduces genetic stroke risk'

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/43k7vr/2013_reporter) has announced the addition of the "2013 Reporter Gene Assays Dashboard Series 1" report to their offering.

Reporter gene assays (RGA) are sensitive and versatile methods used extensively to study regulatory sequences, gene expression, signaling pathways and transcriptional activity, among other applications. Reporter gene assays are widely used by scientists in both industry and academia. As life science suppliers continue improving products and services in the reporter gene assays market, reporter gene assay kits and reagents represent a significant market within the life sciences industry.

In order to explore the characteristics and dynamics of the market for reporter gene assays in depth, this study is the first in the series of Reporter Gene Assays Dashboard for the North American and European markets. This 2013 Dashboard provides a snapshot of the current reporter gene assays market landscape, to establish a foundation of data to which future series of Life Science Dashboards can be compared, giving Dashboard readers the ongoing story of how the market is adapting to new products, new competitors and sales and marketing strategies.

The 2013 Reporter Gene Assays Dashboard was developed from responses to a 27-question survey completed by 433 scientists located in North America and Europe.

This Dashboard reveals key market indicators for the reporter gene assays market as a whole as well as for the following techniques representing market sub-segments:

- Beta-galactosidase (LacZ) assays

- Chloramphenicol acetyltransferase (CAT) assays

- Fluorescent protein related assays, e.g. GFP, YFP, etc.

- Luciferase assays

Continue reading here:
Research and Markets: 2013 Reporter Gene Assays Dashboard Report: Snapshot of the Current Reporter Gene Assays Market ...

Recommendation and review posted by Bethany Smith

Glowing bunnies are a successful early step in a project aimed at engineering mammals that produce medicines in their milk.

In normal light, the eight rabbits all look the samewhite, cute, and begging to be squeezed. But switch to black light, and two stand out by brightly glowing green.

The rabbits were born last month at the University of Istanbul as part of collaboration between universities in Turkey and Hawaii. Sea jelly genes engineered into the bunnies genomes bestowed them with their luminous abilities (you can see more of the rabbits in this video).

The glowing rabbits are certainly not the first transgenic animals to light the nightresearchers have already shown off glowing dogs, monkeys, cats, and many other species, including rabbits (see Glowing Monkeys Inherit Jellyfish Genes and Fluorescent Cats to Help Fight AIDS). The point of the flashy genetic engineering is not to give pet store owners a new product to hawk, but rather to confirm that the techniques researchers use to transfer genes into a genome are working. And in many cases, the greater goal is to develop new ways to study or treat disease.

As reported by The Guardian, the ultimate goal of the Turkish and Hawaiian collaboration is to refine techniques that could one day lead to animals capable of producing medicines in their milk. As Stefan Moisyadi, a University of Hawaii researcher involved in the project told The Guardian:

The final goal is to develop animals to produce beneficial molecules in their milk that can be cheaply extracted, especially in countries that cannot afford big pharma plants that make drugs, that usually cost $1bn to build, and be able to produce their own protein-based medication in animals.

Other groups have already seen some success with this idea, and in 2009, the FDA approved a drug that is purified from the milk of a transgenic goat (see FDA Approves First Pharm Animals). In a TV news interview, Moisyadi also mentions the potential for biologic drugs, such as replacement blood-clotting enzymes for people with hemophilia, to be produced more cheaply in transgenic animals than they are today.

Another cool idea in this space is to develop transgenic goats to produce malaria vaccine in their milk. Last year, researchers at Texas A&M University reported that they had indeed produced such a goat; the question remained whether her daughters would also be capable of making the life-saving medication. If proven successful and safe, the idea would be to take the goats offspring (or other goats like her) to developing countries with malaria outbreaks as a hardy source of vaccine.

Read the original post:
Genetic engineering project begins with glow-in-the-dark rabbits, but it could lead to better disease treatment

Recommendation and review posted by Bethany Smith

Law of Definite Proportions
Chemistry Chapter 2 : Atoms and Elements Tags:/ Acid-base reaction theories Alchemy Analytical chemistry Astrochemistry Biochemistry Crystallography Environm...

By: KabiEdu

Continued here:
Law of Definite Proportions - Video

Recommendation and review posted by Bethany Smith

Seattle Genetics, Inc. (SGEN) recently commenced a phase II study of Adcetris in combination with the current standard of care in treatment-naive patients with diffuse large B-cell lymphoma (:DLBCL).

The open-label, phase II study will evaluate roughly 50 frontline high-risk DLBCL patients, who will receive Adcetris in combination with Rituxan and standard chemotherapy (R-CHOP).

The primary endpoint is to evaluate the complete remission rate and safety of the A+RCHOP regimen. Secondary endpoints include objective response rate, progression-free survival and overall survival.

This study will generate tolerability data as well as antitumor activity data achieved by Adcetris plus the current standard frontline regimen.

In Jun 2013, Seattle Genetics had presented data at the International Conference on Malignant Lymphoma (:ICML) from a phase II study of Adcetrisin patients with relapsed B-cell lymphomas. The study involved 44 patients including 25 DLBCL patients who achieved an objective response rate of 44%.

Seattle Genetics sole marketed antibody-drug conjugate (ADC) product is Adcetris. Adcetris is used for the treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (:ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not suitable for ASCT. Adcetris is also approved for the treatment of systemic anaplastic large cell lymphoma after failure of at least one multi-agent chemotherapy regimen.

ADCs have lately been attracting a lot of interest with major companies entering into collaborations. Seattle Genetics has an alliance with Genentech, a business wing of Roche Holding AG (RHHBY), for the development of ADCs.

Seattle Genetics carries a Zacks Rank #3 (Hold). Currently, companies like Questcor Pharmaceuticals Inc. (QCOR) and Actelion Ltd. (ALIOF) look well positioned with a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on ALIOF

Read the Full Research Report on QCOR

Originally posted here:
SGEN Starts Phase II Study on Adcetris

Recommendation and review posted by Bethany Smith

By: Jet Villa, InterAksyon.com August 16, 2013 8:24 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines -- (UPDATE - 10:12 a.m.) A consultant of Secretary Enrique Ona resigned Friday, calling the Health chiefs position that patients undergoing experimental stem cell therapy should pay unacceptable.

Dr. Anthony Leachon, who is in Davao City, said he emailed his resignation letter to Ona.

It is with deep regret that I'm resigning asDepartment of Health consultant for non-communicable diseases effective today (Friday). I have been privileged and honored to be a part of your administration even as a one peso a year consultant. I value our friendship and camaraderie which started years ago, Leachon, vice president of the Philippine College of Physicians and Onas consultant for non-communicable diseases, wrote.

Because his position is directly opposed to Onas, Leachon told the Health secretary, I believe I have lost your trust and confidence and I might not be effective serving the DOH and fighting the PCP and medical societies ' cause in the service of the Filipino patient.

Leachon was Onas consultant for non-communicable diseases since November 2011.

Ang pinaka-hindi ko nagustuhan ay yung sisingilin ang pasyente kahit clinical trial pa lang. Yon ang unacceptable sa akin (What I disagree with most is charging patients even if what they undergo are just clinical trials. That is unacceptable), Leachon said.

His resignation came as the National Health Institute, the research arm for health sciences of the University of the Philippines-Manila, joined the growing opposition to the Health secretarys stand on experimental stem cell therapy.

Leachon, a cardiologist at the Manila Doctors Hospital, called Onas position a complete violation of the Code of Ethics (for doctors) and being the secretary of health, alam niya dapat yon (he should know that). This is not a sign of ignorance, pero siguro may mga taong iba ang sinasabi sa kaniya (but there may be people telling him otherwise).

Read the original post:
NIH joins opposition to charging patients for experimental stem cell therapy

Recommendation and review posted by Bethany Smith

By: Jet Villa, InterAksyon.com August 16, 2013 8:24 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines -- (UPDATE - 10:12 a.m.) A consultant of Secretary Enrique Ona resigned Friday, calling the Health chiefs position that patients undergoing experimental stem cell therapy should pay unacceptable.

Dr. Anthony Leachon, who is in Davao City, said he emailed his resignation letter to Ona.

It is with deep regret that I'm resigning asDepartment of Health consultant for non-communicable diseases effective today (Friday). I have been privileged and honored to be a part of your administration even as a one peso a year consultant. I value our friendship and camaraderie which started years ago, Leachon, vice president of the Philippine College of Physicians and Onas consultant for non-communicable diseases, wrote.

Because his position is directly opposed to Onas, Leachon told the Health secretary, I believe I have lost your trust and confidence and I might not be effective serving the DOH and fighting the PCP and medical societies ' cause in the service of the Filipino patient.

Leachon was Onas consultant for non-communicable diseases since November 2011.

Ang pinaka-hindi ko nagustuhan ay yung sisingilin ang pasyente kahit clinical trial pa lang. Yon ang unacceptable sa akin (What I disagree with most is charging patients even if what they undergo are just clinical trials. That is unacceptable), Leachon said.

His resignation came as the National Health Institute, the research arm for health sciences of the University of the Philippines-Manila, joined the growing opposition to the Health secretarys stand on experimental stem cell therapy.

Leachon, a cardiologist at the Manila Doctors Hospital, called Onas position a complete violation of the Code of Ethics (for doctors) and being the secretary of health, alam niya dapat yon (he should know that). This is not a sign of ignorance, pero siguro may mga taong iba ang sinasabi sa kaniya (but there may be people telling him otherwise).

Read the rest here:
Consultant quits over DOH chief's stand on stem cell therapy

Recommendation and review posted by Bethany Smith

Aug. 15, 2013 Transposons are DNA elements that can multiply and change their location within an organism's genome. Discovered in the 1940s, for years they were thought to be unimportant and were called "junk DNA." Also referred to as transposable elements and jumping genes, they are snippets of "selfish DNA" that spread in their host genomes serving no other biological purpose but their own existence.

Now Tokuji Tsuchiya and Thomas Eulgem, geneticists at the University of California, Riverside, challenge that understanding. They report online this week in the Proceedings of the National Academy of Sciences that they have discovered a transposon that benefits its host organisms.

Working on the model plant Arabidopsis, they found that the COPIA-R7 transposon, which has jumped into the plant disease resistance gene RPP7, enhances the immunity of its host against a pathogenic microorganism that is representative of a large group of fungus-like parasites that cause various detrimental plant diseases.

"We provide a new example for an 'adaptive transposon insertion' event -- transposon insertions that can have beneficial effects for their respective host organisms -- and uncover the mechanistic basis of its beneficial effects for plants," said Thomas Eulgem, an associate professor of plant cell biology and the senior author of the research paper. "While it has been known for a while that transposon insertions can have positive effects for their respective host organisms and accelerate evolution of their hosts, cases of such adaptive transposon insertions have been rarely documented and are, so far, poorly understood."

The COPIA-R7 transposon affects RPP7 by interfering with the latter's epigenetic code. In contrast to the well known 4-letter genetic DNA code, which provides instructions for the synthesis of proteins, the "epigenetic code" defines the activity states of genes and determines to what extent their genetic information is utilized. Eulgem explained that the transposition of transposons is typically inhibited by epigenetic silencing signals associated with their DNA. Such epigenetic signals are like molecular "flags" or "tags" that are attached to special proteins, around which DNA is wrapped.

A type of molecular flag, referred to as H3K9me2, prohibits transposons from being active and jumping in their host genomes.

"An exciting aspect of our work is that H3K9me2 signals associated with COPIA-R7 have acquired a completely new meaning in RPP7 and promote the activity of this disease-resistance gene," said Eulgem, a member of UC Riverside's Center for Plant Cell Biology. "By modulating levels of this silencing signal in RPP7, plants can adjust the activity of this disease resistance gene.

"Silencing of transposon activity is a complex process that is based on the interplay between different types of epigenetic signals," Eulgem continued. "Typically H3K9me2 is of critical importance for transposon silencing. However, we found H3K9me2 is not important for COPIA-R7 silencing, perhaps because this type of epigenetic signal has acquired a different function within the RPP7 gene. While we found H3K9me2 to promote RPP7 activity, it seems to have lost its function for COPIA-R7 silencing."

Arabidopsis plants use H3K9me2-mediated messenger RNA processing to accurately set RPP7 activity to precisely defined levels. In principle, scientists interested in crop improvement can now use the UCR discovery to design new types of molecular switches based on H3K9me2-mediated messenger RNA processing. Using standard molecular biological methods, transposon sequences that are naturally associated with this epigenetic signal can be inserted into suitable genes and thereby alter the activity levels of these genes.

"Our results are critical for the basic understanding of how transposons can affect the evolution of their hosts -- something not well understood at this time," said Tokuji Tsuchiya, the first author of the research paper and an assistant specialist in Eulgem's lab. "Besides this impact on basic research, the epigenetic mechanism we discovered can possibly be utilized for biotechnological crop improvement. In principle, the switch mechanism we discovered can be applied to all crop species that can be genetically modified."

See more here:
Beneficial jumping gene discovered

Recommendation and review posted by Bethany Smith

Public release date: 15-Aug-2013 [ | E-mail | Share ]

Contact: Todd Kluss tkluss@geron.org 202-587-2839 The Gerontological Society of America

The Gerontological Society of America (GSA) and the National Center for Creative Aging (NCCA) have chosen Nina Kraus, PhD, of Northwestern University as the 2013 recipient of the Gene D. Cohen Research Award in Creativity and Aging.

This award recognizes and honors the seminal work of Gene Cohen, MD, whose research in the field of creativity and aging shifted the conceptual focus from a problem paradigm to one of promise and potential. Cohen inspired individuals to approach longevity asking what wonders can be achieved, not in spite of age, but because of age. The award is presented annually to a professional whose research in the field of creativity and aging demonstrates these positive attributes.

The award presentation will take place at GSA's 66th Annual Scientific Meeting, which will be held from November 20 to 24 in New Orleans. This conference is organized to foster interdisciplinary collaboration among researchers, educators, and practitioners who specialize in the study of the aging process. Visit http://www.geron.org/annualmeeting for further details.

Kraus is a professor of neurobiology & physiology and otolaryngology, and the Hugh Knowles Chair at Northwestern University, where she also directs the Auditory Neuroscience Laboratory.

She investigates the neurobiology underlying speech and music perception and learning-associated brain plasticity. This involves studies of listeners throughout the lifespan, clinical populations, and musicians.

Kraus has pioneered the use of a biological approach that reveals how auditory signals are encoded by a hub of cognitive and sensory influences. This approach reveals the fidelity of the brain's encoding of sound and the impact of experience. She has discovered biological mechanisms of aging and how software-based training and musical experience positively impact the adult brain.

###

The Gerontological Society of America (GSA) is the nation's oldest and largest interdisciplinary organization devoted to research, education, and practice in the field of aging. The principal mission of the Society and its 5,400+ members is to advance the study of aging and disseminate information among scientists, decision makers, and the general public. GSA's structure also includes a policy institute, the National Academy on an Aging Society, and an educational branch, the Association for Gerontology in Higher Education.

Read more here:
Kraus to receive 2013 Gene D. Cohen Award

Recommendation and review posted by Bethany Smith

The Genetics of Familial Pulmonary Arterial Hypertension (PAH)
Recently, Rare Disease Report sat down with Dr. Wendy Chung, Clinical and Medical Geneticist at Columbia University to talk about her labs work in genetic te...

By: rarediseasereport2

Original post:
The Genetics of Familial Pulmonary Arterial Hypertension (PAH) - Video

Recommendation and review posted by Bethany Smith

Jeff "Genetics" Beckham
MD Latino TV presenta a Jeff Beckham en el Tampa Bay Pro Show.

By: MD LATINO MD LATINO

Continue reading here:
Jeff "Genetics" Beckham - Video

Recommendation and review posted by Bethany Smith

Stem Cell and Gene Therapy for CV Disease: Lessons learned and future directions
Les Miller, MD Director of the USF Heart Institute Professor of Cardiovascular Sciences at the USF Health Morsani College of Medicine Cardiology Grand Rounds...

By: DukeClinicalResearch

See the article here:
Stem Cell and Gene Therapy for CV Disease: Lessons learned and future directions - Video

Recommendation and review posted by Bethany Smith

Global Personalized Medicine Diagnostics Market 2012 2016

By: Anjali Kalan

Here is the original post:
Global Personalized Medicine Diagnostics Market 2012 2016 - Video

Recommendation and review posted by sam

TEDMED - Personalized Medicine and It #39;s Challenges (Part 3), Amy Miller, Ph.D.
Amy Miller PhD, Vice President, Policy, Personalized Medicine Coalition -- Discusses what is personalized medicine and its challenges for 2013 TEDMED Great ...

By: personalizedmedicine

Read more here:
TEDMED - Personalized Medicine and It's Challenges (Part 3), Amy Miller, Ph.D. - Video

Recommendation and review posted by sam

TEDMED - Personalized Medicine and It #39;s Challenges (Part 4), Amy Miller, Ph.D.
Amy Miller PhD, Vice President, Policy, Personalized Medicine Coalition -- Discusses what is personalized medicine and its challenges for 2013 TEDMED Great ...

By: personalizedmedicine

View original post here:
TEDMED - Personalized Medicine and It's Challenges (Part 4), Amy Miller, Ph.D. - Video

Recommendation and review posted by sam

TEDMED - Personalized Medicine and It #39;s Challenges (Part 5), Amy Miller, Ph.D.
Amy Miller PhD, Vice President, Policy, Personalized Medicine Coalition -- Discusses what is personalized medicine and its challenges for 2013 TEDMED Great ...

By: personalizedmedicine

Read more:
TEDMED - Personalized Medicine and It's Challenges (Part 5), Amy Miller, Ph.D. - Video

Recommendation and review posted by sam

William Colpin MD. Update in the Management of Traumatic Spinal Cord Injury, Panama 2013.
Update in the Management of Traumatic Spinal Cord Injury, William Coplin MD. 3rd International Neurocritical Care symposium, Panama 2013.

By: NeuroandCriticalCare

Read more:
William Colpin MD. Update in the Management of Traumatic Spinal Cord Injury, Panama 2013. - Video

Recommendation and review posted by sam

Spinal Cord Injury attorney in Dallas
Spinal cord injuries can instantly change a person #39;s life. For those of us who have not suffered such an injury, it is impossible to fully comprehend the phy...

By: Powers Taylor

Original post:
Spinal Cord Injury attorney in Dallas - Video

Recommendation and review posted by sam

Regenerative Medicine Market in the US 2012 2016

By: Anjali Kalan

Original post:
Regenerative Medicine Market in the US 2012 2016 - Video

Recommendation and review posted by sam

My Stem Cell Therapy Fundraiser
Explain how I was able to raise funds toward my Stem Cell Therapy to treat Multiple Sclerosis...

By: Tiffany Talks Multiple Sclerosis

Link:
My Stem Cell Therapy Fundraiser - Video

Recommendation and review posted by simmons

Hello Doctor Zee 24 Taas Dr Nandini Gokulchandran talk show on stem cell therapy treatment
Hello Doctor Zee 24 Taas Dr Nandini Gokulchandran talks about Brain Related different types diseases and for them effective Stem Cell Therapy Treatments Stem...

By: Neurogen Brain and Spine Institute

Read more:
Hello Doctor Zee 24 Taas Dr Nandini Gokulchandran talk show on stem cell therapy treatment - Video

Recommendation and review posted by simmons

Poway, California (PRWEB) August 15, 2013

Robert J. Harman, DVM, Chief Executive Officer of Vet-Stem, Inc., a leading Regenerative Veterinary MedicineTM company located in San Diego, California, has been invited back to speak at the Adult Stem Cell Therapy and Regenerative Medicine Conference in Cleveland, Ohio August 19-21, 2013. The conference is presented by The National Center for the Regenerative Medicine (NCRM), Case Western Reserve University (CWRU), Cleveland Clinic (CC), and University Hospitals Case Medical Center (UHCMC) to bring together a global perspective on regenerative medicine and adult stem cell therapy.

Dr. Harman is scheduled as the first speaker of Session II titled Disease Models for Adult Stem Cell Therapy, and his presentation is One Medicine Natural Veterinary Disease Models.

He stands alone in his expertise in the field of Regenerative Veterinary Medicine among the 273 attendees from 100 institutions in 17 countries that make up the conference. Dr. Harman draws his knowledge from more than 10,000 horse, dog and cat patients treated over the last 10 years in both the U.S. and Canada using proprietary Vet-Stem technology.

Dr. Harman is sharing the podium with Case Western Reserve Universitys own Dr. Arnold Caplan, and revolutionary regenerative medicine companies such as BioTime, Terumo BCT, STROMALab, and Pfizer. Dr. Caplan, a technology pioneer in cell-based therapies in Regenerative Medicine, is a scientific advisor to Vet-Stem, Inc.

About Vet-Stem, Inc.

Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.

More:
Vet-Stem, Inc. Founder and CEO, Robert Harman, DVM, Invited to Speak at the Adult Stem Cell Therapy and Regenerative ...

Recommendation and review posted by simmons

By: Jet Villa, InterAksyon.com August 16, 2013 8:24 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines -- (UPDATE - 10:12 a.m.) A consultant of Secretary Enrique Ona resigned Friday, calling the Health chiefs position that patients undergoing experimental stem cell therapy should pay unacceptable.

Dr. Anthony Leachon, who is in Davao City, said he emailed his resignation letter to Ona.

It is with deep regret that I'm resigning asDepartment of Health consultant for non-communicable diseases effective today (Friday). I have been privileged and honored to be a part of your administration even as a one peso a year consultant. I value our friendship and camaraderie which started years ago, Leachon, vice president of the Philippine College of Physicians and Onas consultant for non-communicable diseases, wrote.

Because his position is directly opposed to Onas, Leachon told the Health secretary, I believe I have lost your trust and confidence and I might not be effective serving the DOH and fighting the PCP and medical societies ' cause in the service of the Filipino patient.

Leachon was Onas consultant for non-communicable diseases since November 2011.

Ang pinaka-hindi ko nagustuhan ay yung sisingilin ang pasyente kahit clinical trial pa lang. Yon ang unacceptable sa akin (What I disagree with most is charging patients even if what they undergo are just clinical trials. That is unacceptable), Leachon said.

His resignation came as the National Health Institute, the research arm for health sciences of the University of the Philippines-Manila, joined the growing opposition to the Health secretarys stand on experimental stem cell therapy.

Leachon, a cardiologist at the Manila Doctors Hospital, called Onas position a complete violation of the Code of Ethics (for doctors) and being the secretary of health, alam niya dapat yon (he should know that). This is not a sign of ignorance, pero siguro may mga taong iba ang sinasabi sa kaniya (but there may be people telling him otherwise).

Continue reading here:
Consultant quits over DOH chief's stand on stem cell therapy

Recommendation and review posted by simmons

by Buena Bernal Posted on 08/15/2013 7:59 PM |Updated 08/16/2013 12:05 AM

PROBE STEM CELL THERAPY. Rep Paulino 'Doy' Leachon files a resolution to probe the conduct of stem cell therapy in the Philippines. Photo grabbed from islandsentinel.com

MANILA, Philippines - Rep Paulino Salvador "Doy" Leachon of Oriental Mindoro's 1st district filed on Thusday, August 15, a house resolution calling for a congressional inquiry in aid of legislation on the conduct of stem cell therapy in the country.

House Resolution 215 was filed a day after Leachon's scheduled privilege speech, calling for the resignation of Health Secretary Enrique Ona over the cabinet official's stand on stem cell therapy.

READ: Leachon asks Ona to resign over stem cell issue

The 40-year-old lawmaker also urged concerned government agencies to step up their regulatory oversight. These agencies include the Department of Health (DOH), the Food and Drug Administration (FDA), and the Professional Regulation Commission (PRC).

First attempt to regulate

Government regulation of stem cell treatment is still in its infancy stage, with the guidelines for accreditation of facilities released only in March.

It is DOH's first attempt at regulating the practice, despite the therapy having been administered by Filipino physicians for years now.

The types of stem cell treatment that are allowed, prohibited, and restricted (i.e. allowed but with limitations) in the facilities to be accredited by August 31 are listed in the released guidelines.

Read more:
Solon calls for probe into stem cell therapy

Recommendation and review posted by simmons

Stem Cell Therapy Treatment for Congenital Muscular Dystrophy by Dr Alok Sharma, Mumbai, India.
Improvement seen in just 5 day after Stem Cell Therapy Treatment for Congenital Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy ...

By: Neurogen Brain and Spine Institute

Link:
Stem Cell Therapy Treatment for Congenital Muscular Dystrophy by Dr Alok Sharma, Mumbai, India. - Video

Recommendation and review posted by Bethany Smith